Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

IMPORTANCE: The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. OBJECTIVE: To assess the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Chodick, Gabriel, Tene, Lilac, Patalon, Tal, Gazit, Sivan, Ben Tov, Amir, Cohen, Dani, Muhsen, Khitam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185600/
https://www.ncbi.nlm.nih.gov/pubmed/34097044
http://dx.doi.org/10.1001/jamanetworkopen.2021.15985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185600/
https://www.ncbi.nlm.nih.gov/pubmed/34097044
http://dx.doi.org/10.1001/jamanetworkopen.2021.15985

Ejemplares similares